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Abstract
Background: The rates of multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) isolates
among Enterobacteriaceae isolates, particularly Klebsiella pneumoniae, have risen substantially worldwide.
Methodology/Principal Findings: To better understand the molecular mechanisms of drug resistance in K. pneumoniae, we
analyzed the drug resistance determinants for K. pneumoniae isolates collected from the 306 Hospital, a tertiary-care
hospital in Beijing, China, for the period of September 1, 2010-October 31, 2011. Drug susceptibility testing, PCR
amplification and sequencing of the drug resistance determinants were performed. Conjugation experiments were
conducted to examine the natural ability of drug resistance to disseminate among Enterobacteriaceae strains using a
sodium azide-resistant Escherichia coli J53 strain as a recipient. Among the 223 consecutive non-repetitive K. pneumoniae
isolates included in this study, 101 (45.3%) were extended-spectrum beta-lactamases (ESBLs) positive. The rates of MDR,
XDR, and PDR isolates were 61.4% (n = 137), 22.0% (n = 49), and 1.8% (n = 4), respectively. Among the tested drug resistance-
associated genes, the following ones were detected at relatively high rates blaCTX-M-10 (80, 35.9%), aacC2 (73, 32.7%), dhfr
(62, 27.8%), qnrS (58, 26.0%), aacA4 (57, 25.6%), aadA1 (56, 25.1%). Results from conjugation experiments indicate that many
of the drug resistance genes were transmissible.
Conclusions/Significance: Our data give a ‘‘snapshot’’ of the complex genetic background responsible for drug resistance
in K. pneumoniae in China and demonstrate that a high degree of awareness and monitoring of those drug resistance
determinants are urgently needed in order to better control the emergence and transmission of drug-resistant K.
pneumoniae isolates in hospital settings.
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Introduction
The emergence and rapid spread of drug-resistant Klebsiella
pneumoniae isolates is becoming a serious antibiotic management
problem and causing a great concern worldwide [1–6]. For
example, by late 2009, the number of unique protein sequences for
beta-lactamases exceeded 890 (http://www.lahey.org/Studies)
[7]. There is an increasing recognition of isolates producing
newer beta-lactamases including the extended-spectrum beta-
lactamase (ESBL), carbapenem-hydrolyzing enzymes (e.g., K.
penumoniae carbapenemase [KPC] types and the metallo-beta-
lactamases [MBLs]) [8–18]. Since the production of newer beta-
lactamases is frequently accompanied by broad-spectrum resis-
tance, the ESBL positivity together with the existence of newer
beta-lactamases should be monitored closely as the emergence of
those highly drug-resistant K. pneumoniae strains will pose a serious
impact on the remaining therapeutic options [19–22]. In a study
based on the Tigecycline Evaluation and Surveillance Trial
(TEST) global surveillance database, the rate of ESBL production
was highest among the K. pneumoniae isolates collected in Latin
America, followed by Asia/Pacific Rim, Europe, and North
America (44.0%, 22.4%, 13.3% and 7.5%, respectively) [23].
Thus the potential of drug resistant K. pneumoniae to be a global
health problem is great and more intensive surveillance and more
in-depth investigation into the molecular mechanisms of drug
resistance in K. pneumoniae isolates are necessary in order to provide
information for the development of effective molecular diagnostic
methods and novel drugs against K. pneumoniae infection.
In the face of increasing resistance among multidrug-resistant
(MDR) gram-negative organisms for which no adequate thera-
peutic options exist, a joint initiative by the European Centre for
Disease Prevention and Control (ECDC) and the Centers for
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Disease Control and Prevention (CDC) recently created a
standardized international definitions for MDR, extensively
drug-resistant (XDR) and pandrug-resistant (PDR) with an aim
to enhance the comparability of data and promote better
comprehension of the problem of highly drug-resistant bacteria
[24]. MDR was defined as acquired non-susceptibility to at least
one agent in three or more antimicrobial categories, XDR was
defined as non-susceptibility to at least one agent in all but two or
fewer antimicrobial categories (i.e. bacterial isolates remain
susceptible to only one or two categories) and PDR was defined
as non-susceptibility to all agents in all antimicrobial categories
[24]. Though there are already many reports of drug-resistant K.
pneumoniae worldwide, the extent of MDR, XDR and PDR K.
pneumoniae isolates among patients is largely unknown. We thus in
this study sought to determine the prevalence of MDR, XDR and
PDR strains and to analyze the drug resistance determinants for K.
pneumoniae isolates collected from patients being treated in the 306
Hospital, a tertiary-care hospital in Beijing, China, for the period
of September 1, 2010-October 31, 2011 with an aim to better
understand the current situation as well as the genetic background
of the drug resistant K. pneumoniae isolates from hospital settings.
Methods
Ethics Statement
All of the investigation protocols in this study were approved by
the institutional ethics committee of the 306 Hospital, Beijing,
China. Written consent was given by the patients for their
information to be stored in the hospital database and used for
research. Permission for using the information in the medical
records of the patients for research purposes was obtained from the
306 Hospital. The Institute ethics committee of the 306 Hospital
reviewed that relevant ethical issues in this study were well
considered.
Study Population, Bacterial Isolate Identification, and
Drug Susceptibility Testing
This is a prospective surveillance study. Consecutive K.
pneumoniae isolates were collected from unique patients being
treated in the 306 Hospital in Beijing, China (which is a 1,100-bed
tertiary-care hospital serving approximately 25,000 in-patients per
year) for the period of September 1, 2010-October 31, 2011. In
the case of duplicate patient samples, the first collected isolate was
chosen. All strains were cultured in Luria–Bertani (LB) medium.
The K. pneumoniae strains were confirmed by phenotypic tests and
16 S rDNA sequencing. Drug susceptibility testing (DST) for the
K. pneumoniae strains was performed using the bioMe´rieux VITEK-
2 AST-GN13 system following manufacturer’s instructions. The
following 18 drugs were tested: ampicillin (AMP), piperacillin/
tazobactam (TZP), ampicillin/sulbactam (SAM), cefazolin (CFZ),
ceftriaxone (CRO), ceftazidime (CAZ), cefepime (FEP), cefotetan
(CTT), ertapenem (ETP), imipenem (IMP), aztreonam (ATM),
ciprofloxacin (CIP), levofloxacin (LVX), gentamicin (GM), tobra-
mycin (TOB), amikacin (AMK), trimethoprim-sulfamethoxazole
(SXT), furadantin (FD). The ESBLs were detected by the
bioMe´rieux VITEK-2 AST-GN13 test (which is claimed to be a
confirmatory ESBL test). In some cases, the ESBL positivity was
further confirmed by the double disk diffusion method [25].
Escherichia coli strains ATCC 25922 and ATCC 35218, K.
pneumoniae strain ATCC 700603 and Pseudomonas aeruginosa strain
ATCC 27853 were used as quality control strains for the DST.
Clinical records of patients from whom the K. pneumoniae isolates
were obtained were reviewed retrospectively.
PCR Amplification and Sequencing
Genomic DNA was extracted using DNeasy Tissue kit (Qiagen;
Valencia, CA, USA). Drug resistance-associated genes were
detected by PCR and sequencing using 37 pairs of primers listed
in Table 1. Direct sequencing of positive amplicons was
conducted. The primers were synthesized by the Beijing Genomics
Institute (BGI, China). PCR was performed in a 50-mL reaction
mixture consisting of 5 mL of 106PCR buffer, 2.5 units of Taq
DNA polymerase (Takara), 0.2 mM of dNTPs, 0.4 mM each of the
primer, and 1 mL chromosomal DNA. All reaction mixtures were
subjected to 30 cycles of 94uC for 1 min, 55uC for 1 min, and
72uC for 2 min. PCR products were purified and sequenced bi-
directionally with the same primers used for PCR by the Beijing
Genomics Institute (BGI, China). DNA sequences were annotated
using the BLAST program at http://www.ncbi.nlm.nih.gov.
Mutations in the gyrA and parC genes were identified by comparing
the DNA sequences with gyrA and parC sequences of the K.
pneumoniae (GenBank accession numbers DQ673325 and
NC009648 for gyrA and parC, respectively).
Conjugation Experiments, Plasmid Analysis, and MLST
Analysis
Transfer of resistance genes by conjugation experiments were
carried out in LB broth using clinical isolates as donors and the E.
coli J53AzR as the recipient as described previously [26]. Cultures
of donor and recipient cells in logarithmic phase (0.5 mL each)
were added to 4 mL of fresh LB broth and incubated overnight
without shaking. Transconjugants were selected on LB plates
containing 100 mg/mL sodium azide for counterselection and
100 mg/mL ampicillin to select for plasmid-encoded resistance.
The drugs tested were purchased from Sigma Chemical Co.
Plasmid DNA from the K. pneumoniae donor strains and E. coli
transconjugants were prepared using the Plasmid Maxprep Kit
(Vigorous Biotechnology, Beijing, China) and were separated on
0.7% agarose gels. Genotyping was determined by MLST
analysis. MLST with seven genes (gapA, infB, mdh, pgi, phoE, rpoB
and tonB) was performed on isolates according to the protocol
described on the K. pneumoniae MLST website (www.pasteur.fr/
mlst). Sequence types (STs) were assigned by using the MLST
database (www.pasteur.fr/mlst/Kpneumoniae.html).
Statistical Analysis
SPSS software (version 15.0) was used for data analysis.
Categorical variables were compared with the chi-square test or
Fisher’s exact test. A p value of ,0.05 was considered to be
statistically significant.
Results
Demographic and Clinical Characteristics of the Patients
From September 1, 2010 to October 31, 2011, a total of 223
non-repetitive patients at the 306 Hospital who had K.
pneumoniae isolates were subjected to DST using 18 antibiotics.
Among which, 137 (61.4%) were MDR isolates, 49 (22.0%)
were XDR isolates, 4 (1.8%) were PDR isolates, and 33 (14.8%)
were other types of isolates. The proportion of the male and
female were 73.5% (n = 164) and 26.5% (n = 59), respectively.
Sixty-eight (30.5%) of the patients were Beijing residents and
the rest were from other provinces of China (non-Beijing
residents). The median (6SD) age of the patients was
74.0620.3 years (range 1.0–98.0 years). The majority of the
patients were from medical ward (97, 43.5%) and intensive care
unit (75, 33.6%). The main source of the specimens was sputum
(168, 75.3%). The proportion of the ESBL positive cases was
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45.3% (n = 101). The proportion of XDR (42, 41.6%) and PDR
(4, 4.0%) cases was significantly higher among patients whose
isolates were ESBL positive as compared with those whose
isolates were ESBL negative. In addition, the proportion of
MDR cases (83, 68.0%) and other types of cases (32, 26.2%)
was significantly higher in patients with ESBL-negative isolates
than that observed for XDR (7, 5.7%) and PDR cases (0). The
detailed information on relevant demographic and clinical
characteristics of the study population is summarized in Table 2.
Drug Susceptibility Patterns of the K. pneumoniae Isolates
DST was conducted for 223 K. pneumoniae isolates and the
detailed information on resistance rates to all tested drugs are listed
in Table 3. The highest resistance rate was observed for AMP,
reaching 99.6% (n = 222), followed by resistance to FD (190,
85.2%), CTT (153, 68.6%), SXT (118, 52.9%), SAM (115,
51.6%), CFZ (114, 51.1%), CRO (110, 49.3%), CAZ (110,
49.3%), ATM (109, 48.9%), and TOB (109, 48.9%). The two
carbapenems tested including ETP and IMP exhibited relatively
lower resistance rates (7.2% and 5.8%, respectively). Notably, the
Table 1. Primers used for PCR and sequencing of drug resistance-associated genes from K. pneumoniae isolates.
Target genes Primer sequence (59 to 39)
Amplicon
size (bp)
Source of
reference
Forward Reverse
blaCTX-M-1 GGT TAA AAA ATC ACT GCG TC TTA CAA ACC GTC GGT GAC GA 876 [2]
blaCTX-M-2 ATG ATG ACT CAG AGC ATT CG TTA TTG CAT CAG AAA CCG TG 876 [29]
blaCTX-M-3 GTT GTT GTT ATT TCG TAT CTT CC CGA TAA ACA AAA ACG GAA TG 934 [10]
blaCTX-M-8 ATG ATG AGA CAT CGC GTT AAG CGG TGA CGA TTT TCG CGG CAG 864 [61]
blaCTX-M-9 GTG ACA AAG AGA GTG CAA CGG ATG ATT CTC GCC GCT GAA GCC 850 [31]
blaCTX-M-10 GCA GCA CCA GTA AAG TGA TGG GCG ATA TCG TTG GTG GTA CC 873 [30]
blaCTX-M-14 ACA ATG ACG CTG GCA GAA CTG TTA CAG CCC TTC GGC GAT GA 512 [64]
blaCTX-M-25 CAC ACG AAT TGA ATG TTC AG TCA CTC CAC ATG GTG AGT 924 [61]
blaSHV-group TTT ATC GGC CYT CAC TCA AGG GCT GCG GGC CGG ATA ACG 896 [32]
blaTEM KAC AAT AAC CCT GRT AAA TGC AGT ATA TAT GAG TAA ACT TGG 899 [32]
blaKPC ATG TCA CTG TAT CGC CGT CT TTT TCA GAG CCT TAC TGC CC 882 [8]
blaNDM GGT TTG GCG ATC TGG TTT TC CGG AAT GGC TCA TCA CGA TC 621 [51]
blaIMP GGA ATA GAG TGG CTT AAT TCT C CCA AAC CAC TAC GTT ATC 624 [27]
blaVIM GGT CTC ATT GTC CGT GAT GGT GAT GAG CTC GAT GAG AGT CCT TCT AGA G 271 [27]
blaOXA-48 TTG GTG GCA TCG ATT ATC GG GAG CAC TTC TTT TGT GAT GGC 743 [47]
blaCMY TGG CCA GAA CTG ACA GGC AAA TTT CTC CTG AAC GTG GCT GGC 462 [65]
blaDHA AAC TTT CAC AGG TGT GCT GGG T CCG TAC GCA TAC TGG CTT TGC 405 [65]
blaFOX AAC ATG GGG TAT CAG GGA GAT G CAA AGC GCG TAA CCG GAT TGG 190 [65]
dhfr GCC AAT CGG GTT ATT GGC AA TGG GAA GAA GGC GTC ACC CTC 357 [15]
qnrA ATT TCT CAC GCC AGG ATT TG GAT CGG CAA AGG TTA GGT CA 627 [62]
qnrB GAT CGT GAA AGC CAG AAA GG ACG ATG CCT GGT AGT TGT CC 469 [62]
qnrC GGG TTG TAC ATT TAT TGA ATC G CAC CTA CCC ATT TAT TTT CA 307 [34]
qnrD CGA GAT CAA TTTA CGG GGA ATA AAC AAG CTG AAG CGC CTG 533 [33]
qnrS ACG ACA TTC GTC AAC TGC AA TAA ATT GGC ACC CTG TAG GC 417 [28]
aac(69)-Ib-cr TTG CGA TGC TCT ATG AGT GGC TA CTC GAA TGC CTG GCG TGT TT 482 [35]
qepA AAC TGC TTG AGC CCG TAG AT GTC TAC GCC ATG GAC CTC AC 596 [34]
gyrA CGA CCT TGC GAG AGA AAT GTT CCA TCA GCC CTT CAA 626 [54]
parC TAC GTC ATC ATG GAC AGG GCC ACT TCA CGC AGG TTG 460 [37]
aacA4 ATG ACT GAG CAT GAC CTT GCG TTA GGC ATC ACT GCG TGT TCG 540 [38]
aacC1 ATG GGC ATC ATT CGC ACA TGT AGG TTA GGT GGC GGT ACT TGG GTC 873 [38]
aacC2 ATG CAT ACG CGG AAG GCA ATA AC CTA ACC GGA AGG CTC GCA AG 861 [38]
aadA1 ATG AGG GAA GCG GTG ATC G TTA TTT GCC GAC TAC CTT GGT G 792 [38]
aadB ATG GAC ACA ACG CAG GTC GC TTA GGC CGC ATA TCG CGA CC 534 [38]
aphA6 ATG GAA TTG CCC AAT ATT ATT C TCA ATT CAA TTC ATC AAG TTT TA 781 [38]
armA AGG TTG TTT CCA TTT CTG AG TCT CTT CAT TCC CTT CTC C 591 [57]
rmtB CCC AAA CAG ACC GTA GAG GC CTC AAA CTC GGC GGG CAA GC 585 [57]
Integron I GGC ATC CAA GCA CAA G AAG CAG ACT TGA CCT GA Variable [63]
doi:10.1371/journal.pone.0042280.t001
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rates of resistance to most drugs were much higher among ESBL
positive isolates than ESBL negative isolates.
Drug Resistance Determinants of the K. pneumoniae
Isolates
PCR and sequencing analysis were conducted for 223 K.
pneumoniae isolates to analyze ESBL genes as well as drug resistance
determinants conferring resistance to carbapenems, folate pathway
inhibitors, fluoroquinolones, and aminoglycosides. The detailed
information on the percentage of drug resistance-associated genes
detected in K. pneumoniae isolates were summarized in Table 4 and
Table 5. The percentage of isolates with 8 or more drug resistance-
associated genes was 24.2% (n = 54). Among the beta-lactamase
genes, the most frequently detected ones include: blaCTX-M-10 (80,
35.9%), blaSHV-1 (55, 24.7%), blaSHV-11 (47, 21.1%), blaCTX-M-1
(37, 16.6%), blaCTX-M-14 (37, 16.6%), blaCTX-M-15 (34, 15.2%) and
blaCTX-M-3 (32, 14.3%). Except for blaNDM, all the other 4
examined carbapenemase genes including blaKPC-2 (3, 1.3%),
blaIMP (1, 0.4%), blaVIM (1, 0.4%), and blaOXA-48 (5, 2.2%) were
detected in this study. The prevalence of AmpC beta-lactamases
including blaCMY-2, blaDHA-1 and blaFOX were 3.1%, 4.0% and 0,
respectively in this study. Among the 7 plasmid-encoded
fluoroquinolone resistance-associated genes including qnrA, qnrB,
qnrC, qnrD, qnrS, aac(69)-Ib-cr, and qepA, the highest rates were
observed for qnrS (58, 26.0%) and aac(69)-Ib-cr (53, 23.8%). In
addition, gyrA gene mutations including T247A (Ser83Ile) (21,
9.4%), C248T (Ser83Phe) (15, 6.7%), and A260C (Asp87Ala) (16,
7.2%) were identified. No mutations were detected in parC gene.
Among the aminoglycosides resistance-associated genes, the
highest rates were observed for aacC2 (73, 32.7%), aacA4 (57,
25.6%), and aadA1 (56, 25.1%). The prevalence of the plasmid-
encoded 16 S rRNA methylases armA and rmtB were detected to be
5.8% and 3.6%, respectively. Class 1 integrons were detected in
47.5% (n = 106) of the isolates. In order to evaluate the correlation
between phenotypic and genotypic drug resistance profiles, we also
calculated the proportion of antibiotic resistance-associated genes
among the phenotypic resistant isolates as well as the phenotypic
susceptible isolates. We found that while some of the previously
reported resistance-associated genes were indeed detected at
relatively higher rates among corresponding phenotypic resistant
Table 2. Demographic and clinical characteristics of the patients.
Characteristics
Total
n=223 (%)
Patients infected
with MDR isolates
n=137 (%)
Patients infected
with XDR isolates
n=49 (%)
Patients infected
with PDR isolates
n=4 (%)
Patients infected with
other types of isolates
n=33 (%) P value
Gender 0.991
Male 164 (73.5) 101 (73.7) 35 (71.4) 4 (100) 24 (72.7)
Female 59 (26.5) 36 (26.3) 14 (28.6) 0 9 (27.3)
Age group, years 0.400
,18 7 (3.1) 6 (4.4) 0 0 1 (3.0)
18–64 64 (28.7) 39 (28.5) 11 (22.4) 2 (50.0) 12 (36.4)
.64 152 (68.2) 92 (67.2) 38 (77.6) 2 (50.0) 20 (60.6)
Residence situation 0.862
Beijing resident 68 (30.5) 40 (29.2) 17 (34.7) 0 11 (33.3)
Non-Beijing resident 155 (69.5) 97 (70.8) 32 (65.3) 4 (100.0) 22 (66.7)
Hospital location 0.199
Emergency room 9 (4.0) 7 (5.1) 2 (4.1) 0 0
Intensive care unit 75 (33.6) 51 (37.2) 17 (34.7) 0 7 (21.2)
Medical ward 97 (43.5) 59 (43.1) 18 (36.7) 2 (50.0) 18 (54.5)
Surgical ward 42 (18.8) 20 (14.6) 12 (24.5) 2 (50.0) 8 (24.2)
Sources of specimens 0.187
Sputum 168 (75.3) 108 (78.8) 34 (69.4) 3 (75.0) 23 (69.7)
Urine 14 (6.3) 7 (5.1) 7 (14.3) 0 0
Throat or nose swabs 21 (9.4) 11 (8.0) 2 (4.1) 0 8 (24.2)
Catheters 3 (1.3) 2 (1.5) 1 (2.0) 0 0
Blood 10 (4.5) 4 (2.9) 3 (6.1) 1(25.0) 2 (6.1)
Puncture fluid 1 (0.4) 1 (0.7) 0 0 0
Drainage fluid 1 (0.4) 1 (0.7) 0 0 0
Pleural effusion 2 (0.9) 1 (0.7) 1 (2.0) 0 0
Plus 1 (0.4) 1 (0.7) 0 0 0
Bile 2 (0.9) 1 (0.7) 1 (2.0) 0 0
ESBL ,0.001
Positive 101 (45.3) 54 (39.4) 42 (85.7) 4(100.0) 1 (3.0)
Negative 122 (54.7) 83 (60.6) 7 (14.3) 0 32 (97.0)
doi:10.1371/journal.pone.0042280.t002
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isolates, some others were detected in very low proportion of the
phenotypic resistant isolates. In addition, some of the resistance-
associated genes were also detected in a sizable proportion of the
phenotypic susceptible isolates.
Characteristics of Carbapenem-resistant K. pneumoniae
Isolates
Among the 223 isolates, 16 were detected to be carbapenem-
resistant and were used for further characterization. Most of the
patients from whom the isolates obtained were male 87.5% (14/
16) and aged patients (all were 56 years old or above). Among the
14 patients whose treatment outcome information was available, 6
died. Although carbapenemase genes were detected only in 7 of
the 16 isolates, the majority of them exhibited resistance to a high
number of drugs and contained a variety of corresponding drug
resistance-associated genes. The proportion of MDR, XDR and
PDR were 12.5% (n = 2), 62.5% (n = 10), 25.0% (n = 4), respec-
tively. The more detailed characteristics of those carbapenem-
resistant isolates are shown in Table S1.
Transmissibility of Drug Resistance of ESBL Positive MDR,
XDR and PDR K. pneumoniae Isolates
Twelve K. pneumoniae isolates including 4 MDR, 4 XDR, and 4
PDR isolates were selected to test the natural transmissibility of
antibiotic resistance by conjugation experiments. As shown in
Table 6, the resistance to various drugs and the corresponding
resistance-associated genes were transferred in all tested isolates,
though to different extent. The most frequently transferred genes
include aac(69)-Ib-cr (6/7, 85.7%), blaCTX-M-14 (4/5, 80.0%),
blaCTX-M-9 (2/3, 66.7%), aacA4 (5/8, 62.5%) and blaSHV-11 (4/8,
50.0%). Five transconjugants contained plasmids with the same
size as those in their respective donors (TZSKP-1, 9, 15, 146, and
Table 4. Percentage of beta-lactamase antibiotics resistance-associated genes detected in K. pneumoniae isolates.
Target antimicrobial
category
Resistance-associated
genes
Resistance-associated genes
detected in phenotypic
resistant isolates, n/Na (%)
Resistance-associated genes
detected in phenotypic
susceptible isolates, n/Nb (%)
Resistance-associated genes
detected in all isolates, n/Nc
(%)
Antipseudomonal
penicillins + beta
-lactamase inhibitors,
penicillins + beta
-lactamase inhibitors,
1st and 2nd generation
cephalosporins, 3rd
and 4th generation
cephalosporins,
cephamycins (n=204)
blaCTX-M-1 35/204 (17.2) 2/19 (10.5) 37/223 (16.6)
blaCTX-M-2 1/204 (0.5) 1/19 (5.3) 2/223 (0.9)
blaCTX-M-3 31/204 (15.2) 1/19 (5.3) 32/223 (14.3)
blaCTX-M-8 20/204 (9.8) 2/19 (10.5) 22/223 (9.9)
blaCTX-M-9 18/204 (8.8) 2/19 (10.5) 20/223 (9.0)
blaCTX-M-14 37/204 (18.1) 0 37/223 (16.6)
blaCTX-M-15 34/204 (16.7) 0 34/223 (15.2)
blaCTX-M-10 76/204 (37.3) 4/19 (21.1) 80/223 (35.9)
blaCTX-M-25 2/204 (1.0) 1/19 (5.3) 3/223 (1.3)
blaCTX-M-55 3/204 (1.5) 0 3/223 (1.3)
blaSHV-1 55/204 (27.0) 0 55/223 (24.7)
blaSHV-2 2/204 (1.0) 0 2/223 (0.9)
blaSHV-11 44/204 (21.6) 3/19 (15.8) 47/223 (21.1)
blaSHV-85 15/204 (7.4) 0 15/223 (6.7)
blaTEM-1 19/204 (9.3) 0 19/223 (8.5)
blaTEM-186 3/204 (1.5) 0 3/223 (1.3)
blaCMY-2 7/204 (3.4) 0 7/223 (3.1)
blaDHA-1 9/204 (4.4) 0 9/223 (4.0)
blaFOX 0 0 0
Carbapenems (n = 16) blaKPC-2 3/16 (18.8) 0 3/223 (1.3)
blaNDM-1 0 0 0
blaIMP 1/16 (6.3) 0 1/223 (0.4)
blaVIM 1/16 (6.3) 0 1/223 (0.4)
blaOXA-48 5/16 (31.3) 0 5/223 (2.2)
an/N: No. of designated drug resistance-associated genes/No. of isolates resistant to the corresponding drugs.
bn/N: No. of designated drug resistance-associated genes/No. of isolates susceptible to the corresponding drugs.
cn/N: No. of designated drug resistance-associated genes/No. of all isolates.
doi:10.1371/journal.pone.0042280.t004
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208) (Figure 1). In addition, the transconjugant for TZSKP-82
harbored new plasmid with different size than that in the donor
strain. The phylogenetic tree based on the MLST analysis results
for the isolates is shown in Figure 2. Seven different STs were
identified for those 12 isolates. Three isolates (TZSKP-1, 9, and
82) belonged to ST15, three isolates (TZSKP-13, 15, and 17)
belonged to ST11, two isolates (TZSKP-228 and 245) belonged to
ST218, and the rest of the isolates had unique STs. The
epidemiological links were further determined for the patients
from whom the clustered isolates were obtained.
Discussion
Worldwide emergence and dissemination of ESBL and
carbapenemase genes among Enterobacteriaceae, especially in K.
pneumoniae isolates, poses a considerable threat to public health.
The major goal of this study was to evaluate the current situation
and genetic background of drug-resistant K. pneumoniae isolates
from patients in hospital settings. The highest and lowest resistance
rates were observed for penicillins (99.6%) and carbapenems
(7.2%), respectively. The rates of MDR, XDR and PDR isolates
observed in this study are alarmingly high. This could cause
difficulty in treating K. pneumoniae-associated infections since fewer
and fewer effective drugs are available for treating those highly
drug-resistant isolates. We also found that the proportion of MDR
and other types of cases was significantly higher in patients with
ESBL-negative isolates than that for XDR and PDR cases. This
could be partially explained by the fact that the ESBL-positive
isolates are normally resistant to many drugs, leaving only a few
effective drugs available for treatment, which could lead to further
resistance to those drugs. Indeed, this study further reveals that
resistance to most of the drugs was found to be associated with
ESBL positivity. Infections due to those ESBL positive and highly
resistant strains are reported to be associated with higher
morbidity and mortality rates [19–22], thus globally coordinated
surveillance of epidemiology of those resistant isolates are
warranted.
Another goal of this study was to evaluate the correlation
between resistance phenotypes and the genetic determinants
clinical K. penumoniae isolates, so as to give a ‘‘snapshot’’ of the
background of those resistant isolates. A striking feature of this
study is the large number of antibiotic resistance-associated genes
detected in the examined isolates. We also found that while some
of the previously reported resistance-associated genes were indeed
detected at relatively higher rates among corresponding pheno-
typic resistant isolates, some others were detected in very low
proportion of the phenotypic resistant isolates, suggesting the
existence of unknown drug resistance mechanisms such as reduced
permeability of the outer membrane or up-regulated unknown
efflux pumps in some clinical isolates [27,28]. In addition, some of
Table 5. Percentage of non-beta-lactamase antibiotics resistance-associated genes detected in K. pneumoniae isolates.
Target antimicrobial
category
Resistance-associated
genes
Resistance-associated genes
detected in phenotypic
resistant isolates, n/Na (%)
Resistance-associated genes
detected in phenotypic
susceptible isolates, n/Nb (%)
Resistance-associated genes
detected in all isolates, n/Nc
(%)
Folate pathway
inhibitors (n = 118)
Dhfr 52/118(44.1) 10/105 (9.5) 62/223 (27.8)
Fluoroquinolones
(n = 90)
qnrA 1/90 (1.1) 1/133 (0.8) 2/223 (0.9)
qnrB 33/90 (36.7) 6/133 (4.5) 39/223 (17.5)
qnrC 1/90 (1.1) 1/133 (0.8) 2/223 (0.9)
qnrD 23/90 (25.6) 12/133 (9.0) 35/223 (15.7)
qnrS 22/90 (24.4) 36/133 (27.1) 58/223 (26.0)
aac(69)-Ib-cr 45/90 (50.0) 8/133 (6.0) 53/223 (23.8)
qepA 1/90 (1.1) 1/133 (0.8) 2/223 (0.9)
gyrA mutations
T247A(Ser83Ile) 18/90 (20.0) 3/133 (2.3) 21/223 (9.4)
C248T (Ser83Phe) 12/90 (13.3) 3/133 (2.3) 15/223 (6.7)
A260C(Asp87Ala) 13/90 (14.4) 3/133 (2.3) 16/223 (7.2)
parC mutations None None None
Aminoglycosides
(n = 110)
aacA4 50/110 (45.5) 7/113 (6.2) 57/223 (25.6)
aacC1 3/110 (2.7) 0 3/223 (1.3)
aacC2 66/110 (60.0) 7/113 (6.2) 73/223 (32.7)
aadA1 49/110 (44.5) 7/113 (6.2) 56/223 (25.1)
aadB 4/110 (3.6) 0 4/223 (1.8)
aphA6 1/110 (0.9) 0 1/223 (0.4)
armA 13/110 (11.8) 0 13/223 (5.8)
rmtB 8/110 (7.3) 0 8/223 (3.6)
an/N: No. of designated drug resistance-associated genes/No. of isolates resistant to the corresponding drugs.
bn/N: No. of designated drug resistance-associated genes/No. of isolates susceptible to the corresponding drugs.
cn/N: No. of designated drug resistance-associated genes/No. of all isolates.
doi:10.1371/journal.pone.0042280.t005
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Table 6. Transmissibility of drug resistance of ESBL positive MDR, XDR and PDR K. pneumoniae isolates by conjugation.
K. pneumoniae isolates Resistance profile of K. pneumoniae isolatesa,b
Resistance-associated genes detected in K.
pneumoniae isolatesb
MDR isolates
TZSKP-9 AMP,SAM,CFZ,CRO,CAZ,FEP,ATM,CIP,LVX,SXT,FD blaCTX-M-14,dhfr
TZSKP-28 AMP,SAM,CFZ,CRO,CAZ,FEP,ATM,GM,TOB,SXT,FD blaSHV-11
TZSKP-40 AMP,SAM,CFZ,CRO,CAZ,FEP,ATM,GM,TOB,SXT,FD blaCTX-M-14,blaCTX-M-10,blaSHV-11,blaTEM-1,qnrS,aacC2
TZSKP-208 AMP,SAM,CFZ,CRO,CAZ,FEP,ATM,SXT,FD blaCTX-M-9,blaCTX-M-10,blaSHV-11,qnrS
XDR isolates
TZSKP-13 AMP,SAM,CFZ,CRO,CAZ,FEP,ATM,CIP,LVX,TOB,AMK,SXT,FD blaCTX-M-14,dhfr,qnrB,aacA4
TZSKP-15 AMP,SAM,CFZ,CRO,CAZ,FEP,CTT,ETP,IMP,ATM,CIP,LVX,
GM,TOB,AMK,SXT,FD
blaCTX-M-1,blaCTX-M-14,blaCTX-M-10,blaSHV-
11,blaTEM,dhfr,qnrA,qnrB,aac(69)-Ib-cr,aacA4,aadA1
TZSKP-146 AMP,TZP,SAM,CFZ,CRO,CAZ,FEP,ATM,CIP,LVX,GM,TOB,
AMK,SXT,FD
blaCTX-M-1,blaCTX-M-3,blaCTX-M-9,blaCTX-M-10,blaSHV-
11,blaTEM,dhfr,qnrD,aac(69)-Ib-cr,aacA4,aacC2,aadA1
TZSKP-228 AMP,TZP,SAM,CFZ,CRO,CAZ,FEP,CTT,ETP,IPM,ATM,TOB,
AMK,SXT
blaCTX-M-3,blaCTX-M-10,blaSHV-11,blaTEM-1,blaKPC-
2,blaIMP,blaVIM,blaOXA-48,dhfr,qnrD,qnrS,aac(69)-Ib-
cr,aacA4,aadB,aphA6
PDR isolates
TZSKP-1 AMP,TZP,SAM,CFZ,CRO,CAZ,FEP,CTT,ETP,IMP,ATM,CIP,
LVX,GM,TOB,AMK,SXT,FD
blaCTX-M-3,blaCTX-M-10,blaSHV-11,dhfr,qnrB,aac(69)-Ib-
cr,aacA4,aacC2
TZSKP-17 AMP,TZP,SAM,CFZ,CRO,CAZ,FEP,CTT,ATM,CIP,LVX,GM,
TOB,AMK,SXT,FD
blaCTX-M-2,blaCTX-M-14,blaCTX-M-10,blaSHV-11,blaTEM-
1,blaCMY2,blaDHA1,dhfr,qnrS,aac(69)-Ib-
cr,aacA4,aacC2,aadA1
TZSKP-82 AMP,TZP,SAM,CFZ,CRO,CAZ,FEP,CTT,ETP,IPM,ATM,CIP,
LVX,GM,TOB,AMK,SXT,FD
blaCTX-M-3,blaCTX-M-9,blaCTX-M-10,blaOXA-48,aac(69)-Ib-
cr,aacA4,aacC2,armA
TZSKP-245 AMP,TZP,SAM,CFZ,CRO,CAZ,FEP,CTT,ETP,IPM,ATM,CIP,
LVX,GM,TOB,AMK,SXT,FD
blaCTX-M-10,blaTEM-1,blaKPC-2,dhfr,aac(69)-Ib-cr,aacA4,aacC2
aAbbreviation of drugs: AMP, Ampicillin; TZP, Piperacillin/Tazobactam; SAM, Ampicillin/Sulbactam; CFZ, Cefazolin; CRO, Ceftriaxone; CAZ, Ceftazidime; FEP, Cefepime;
CTT, efotetan; ETP, Ertapenem; IMP, Imipenem; ATM, Aztreonam; CIP, Ciprofloxacin; LVX, Levofloxacin; GM, Gentamycin; TOB, Tobramycin; AMK, Amikacin; SXT,
Trimethoprim-Sulfamethoxazole; FD, Furadantin.
bThe ones found in both donor strains and transconjugants were underlined to demonstrate the difference.
doi:10.1371/journal.pone.0042280.t006
Figure 1. Analysis of plasmid DNA from K. pneumoniae parental donor strains (Designated D) and derived E. coli transconjugants
(Designated T) by agarose gel electrophoresis. Lanes: 1, molecular marker (l-Hind b digest DNA Marker, TaKaRa Code: D3403A); 2, TZSKP-1; 3,
Transconjugant from TZSKP-1; 4, TZSKP-9; 5, Transconjugant from TZSKP-9; 6, TZSKP-13; 7, Transconjugant from TZSKP-13; 8, TZSKP-15; 9,
Transconjugant from TZSKP-15; 10, TZSKP-17; 11, Transconjugant from TZSKP-17; 12, TZSKP-28; 13, Transconjugant from TZSKP-28; 14, TZSKP-40; 15,
Transconjugant from TZSKP-40; 16, TZSKP-82; 17, Transconjugant from TZSKP-82; 18, TZSKP-146; 19, Transconjugant from TZSKP-146; 20, TZSKP-208;
21, Transconjugant from TZSKP-208; 22, TZSKP-228; 23, Transconjugant from TZSKP-228; 24, TZSKP-245; 25, Transconjugant from TZSKP-245.
doi:10.1371/journal.pone.0042280.g001
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the resistance-associated genes were also detected in a sizable
proportion of the phenotypic susceptible isolates, suggesting that
individual resistance gene alone is not sufficient to cause resistance
phenotype and only when some of them were accumulated can the
resistance become detectable in the clinical isolates.
Rapid detection of genetic determinants associated with drug
resistance in clinical K. pneumoniae isolates is crucial for appropriate
antimicrobial therapy and infection control measures. We detected
relatively high percentage of previously reported genes associated
with resistance to beta-lactams [2,10,29–32], fluoroquinolones
[28,33–37], aminoglycosides [38,39], and folate pathway inhibi-
tors [15] in K. pneumoniae isolates. CTX-M-type beta-lactamase
genes (such as blaCTX-M-14 and blaCTX-M-15) have been reported to
be prevalent worldwide [40–42]. For example, a recent study from
China reported that among the 21 K. pneumoniae isolates from 1270
specimens collected in a prospective multi-center study in eight
teaching hospitals in China from June to December in 2007, 3
were detected to have blaCTX-M-14 (3, 14.3%) [40]. Another study
conducted in Scotland showed that 16 of the 219 (7.3%) clinical
isolates of K. pneumoniae collected in 2006 and 2007 at the Royal
Infirmary of Edinburgh, Scotland had blaCTX-M-15 [41]. In the
present study, the highest rate of CTX-M-type beta-lactamase
genes was observed for blaCTX-M-10 (35.9%), followed by blaCTX-M-
1 (16.6%), blaCTX-M-14 (16.6%), and blaCTX-M-15 (15.2%). The rates
of the non-ESBL SHV-type beta-lactamase genes blaSHV-1 and
blaSHV-11 genes were 24.7% and 21.1%, respectively in this study,
which were relatively lower compared to that reported by some
previous studies conducted in other regions. For example,
according to a study conducted in Korea, the rates of the
blaSHV-1 and blaSHV-11 genes among K. pneumoniae isolates collected
from May to July, 2002 were 35% (50/142) and 62% (62/142),
respectively [43]. Another study from Brazil reported that 55.8%
(29/52) of the K. pneumoniae isolates collected in Recife, PE, Brazil
during 1998 to 2005 harbored the blaSHV genes [44]. Thus, the
prevalence of some beta-lactamase genes such as the blaSHV genes
could be greatly variable geographically and timewise.
The more recently reported carbapenemases genes (such as
blaIMP, blaVIM, blaNDM, plasmid-mediated clavulanic acid-inhibited
class A beta-lactamases genes such as blaKPC, and the class D beta-
lactamase gene blaOXA-48) were rarely detected or undetected in
this study. Carbapenemases increasingly have been reported in
Enterobacteriaceae in the past decade. KPC carbapenemases have
been reported in the United States and then worldwide [6,8]. VIM
and IMP metallo-beta-lactamases also have been reported in many
regions of the world, with a higher prevalence in southern Europe
and Asia [1,5,45–47]. Carbapenemases of the oxacillinase-48 type
(OXA-48) have been identified mostly in Mediterranean and
European countries and in India [48,49]. Although the world-
alarming New Delhi metallo-beta-lactamase-1 (NDM-1) was not
detected in this study, it has been detected worldwide since it was
first identified in India and its variants have emerged [13,50–52].
Thus resistance caused by those recently emerging beta-lactamases
is still worrisome and needs continuous monitoring. The
association of alterations in gyrA (gene encoding for GyrA subunit
of DNA gyrase) and parC (gene encoding for ParC subunit of DNA
topoisomerase IV) with fluoroquinolone resistance in K. pneumoniae
is still not clear. Some studies suggested that in K. pneumoniae, DNA
gyrase A is a primary target of quinolones and that ParC
alterations play a complementary role in the development of
higher-level fluoroquinolone resistance [53,54], while a study
reported that hypermutation in K. pneumoniae is uncommon and
does not contribute to accumulation of gyrA mutations or directly
to ciprofloxacin resistance [55]. We identified 3 types of gyrA
mutations including the previously reported C248T (Ser83Phe)
Figure 2. Phylogenetic tree for the 7 housekeeping loci in K. pneumoniae constructed using the UPGMA method, displaying the
clonal relationship among the K. pneumoniae isolates.
doi:10.1371/journal.pone.0042280.g002
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and A260C (Asp87Ala) [53] and the unreported T247A (Ser83Ile).
No mutations in parC were detected in this study. The plasmid-
encoded 16 S rRNA methylases armA and rmtB has emerged as a
new mechanism of resistance to aminoglycosides, and the
concomitant presence of armA or rmtB with blaCTX-M type beta-
lactamase genes, especially the group 1 (CTX-M-3 and CTXM-
15) or group 9 (CTX-M-14), among amikacin-resistant ESBL-
producing K. pneumoniae isolates was reported in Taiwan and
Belgium [56,57]. In this study, both armA and rmtB were detected
(5.8% and 3.6%, respectively). One isolate was found to harbor
both armA and rmtB genes, and consistent with previous reports,
the armA and rmtB genes were coexistent with at least one of the
blaCTX-M type beta-lactamases tested in this study.
Our study further confirmed the notion that patients infected
with carbapenem-resistant K. pneumoniae isolates normally have
worse treatment outcome. In addition, the conjugation results
suggest that certain ESBL genes (such as blaCTX-M-14), aac(69)-Ib-cr
and aacA4 were frequently co-transmitted and co-selected in MDR,
XDR and PDR isolates and can be naturally transferred to
susceptible E. coli strains by conjugation. Five transconjugants
contained plasmids with the same size as those in their respective
donors. Nevertheless, plasmids of the same sizes found in both
donor and recipient isolates could not guarantee that the resistance
transfer was plasmid-mediated. A subsequent DNA-DNA hybrid-
ization experiment with probes made by the respective resistance
genes is warranted to show that the plasmids of the same sizes do
carry the same resistance genes. On the other hand, we noticed
that plasmids were not identified in some of the donor and
recipient isolates. This could be explained by the existence of some
other non-plasmid-mediated mechanisms involved in the occur-
rence and transfer of drug resistance in those isolates. For example,
the drug resistance-associated genes could be carried on chromo-
somally located transposons and integrons. Although the isolate
TZSKP-28 was detected to be ESBL-positive, only the non-ESBL
blaSHV-11 gene was detected in it. After conjugation experiments,
the recipient strain became multidrug resistant and again only the
blaSHV-11 was detected. We also noticed that the beta-lactamase
genes found in the transconjugants of the isolates TZSKP-1 and
TZSKP-40 (blaSHV-11 or blaTEM-1) were not ESBLs, either. This
result suggested that some other mechanisms may be involved in
causing the ESBL positivity and MDR phenotypes in those
isolates. As horizontal transmission event can result in the
acquisition of multidrug resistance by wild-type strains, thus this
could presumably contribute to the rapid increase in the
prevalence of multidrug resistance among clinical bacteria.
Another important aspect for infection control is to know whether
there is a clonal spread among the highly drug-resistant isolates.
Relatively diverse genotypes were identified for those 12 isolates
used in conjugation analysis by MLST analysis. Three clusters
(which belonged to ST15, ST11, and ST218, respectively) each
consisted of 2 or 3 isolates were detected and the epidemiological
links were not observed for the patients from whom the clustered
isolates were obtained. Further investigation of the transmission
patterns of a larger sample of drug-resistant K. pneumoniae isolates
by MLST analysis is warranted and which is currently underway.
Emerging plasmid-encoded ESBLs and carbapenemases are
increasingly reported worldwide [58]. Carbapenemase production
encoded by genes located on mobile genetic elements is typically
accompanied by genes encoding resistance to other drug classes,
and are frequently located on the same mobile DNA elements
such as integrons, which act as bacterial recombination systems
that mediate the capture and expression of gene cassettes and are
considered as the primary mechanism for antibiotic resistance
gene acquisition among bacteria and are frequently associated
with transposons and conjugative plasmids (http://integrall.bio.
ua.pt 2009) [59,60]. In this study, class 1 integrons were detected
in a relatively high percentage of the isolates. Further sequencing
analysis of class 1 integrons and gene cassette arrays is currently
undergoing in the lab.
In summary, our results indicate that there is a high prevalence
and possible transmission of MDR, XDR and PDR K. pneumoniae
isolates among hospitalized patients. In addition, our data give a
‘‘snapshot’’ of the complex genetic background responsible for
drug resistance in those highly drug-resistant K. pneumoniae isolates.
Thus our study demonstrate that a high degree of awareness and
monitoring of those drug resistance determinants are urgently
needed in order to better control the emergence and transmission
of drug-resistant K. pneumoniae isolates in hospital settings.
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